Compare CPOP & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPOP | NNVC |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8M | 21.2M |
| IPO Year | 2020 | 2008 |
| Metric | CPOP | NNVC |
|---|---|---|
| Price | $0.29 | $1.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 48.2K | ★ 481.0K |
| Earning Date | 11-17-2025 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.85 |
| 52 Week High | $2.60 | $2.23 |
| Indicator | CPOP | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 50.04 | 63.87 |
| Support Level | $0.21 | $1.35 |
| Resistance Level | $0.35 | $1.87 |
| Average True Range (ATR) | 0.03 | 0.16 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 60.76 | 76.90 |
Pop Culture Group Co Ltd hosts entertainment events, operates hip-hop-related online programs, and provides event planning and execution services and marketing services to corporate clients. It generates revenue from Event Hosting business by providing sponsorship packages to advertisers in exchange for sponsorship fees and by selling tickets for those concerts. The company has various operations services out of which Brand Promotion earns maximum revenue, following by Event Hosting, and Event Planning and Execution.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.